OncoMatch/Clinical Trials/NCT04516447
A Study of ZN-c3 in Patients With Ovarian Cancer
Is NCT04516447 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for solid tumor.
Treatment: ZN-c3 · Carboplatin · Pegylated liposomal doxorubicin · Paclitaxel · Gemcitabine · Bevacizumab — This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of ZN-c3 in combination with other drugs.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Ovarian Cancer
Disease stage
Grade: high-grade
Measurable disease per RECIST version 1.1.
Prior therapy
Lab requirements
Blood counts
ANC ≥ 1.5 × 10^9/L (excluding measurements after growth factors); Platelet count ≥ 100 × 10^9/L (excluding measurements after transfusion or growth factors)
Kidney function
Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 60 mL/min
Liver function
ALT and AST ≤3 × ULN (≤ 5 x ULN if due to liver metastases); total serum bilirubin ≤ 1.5 × ULN or ≤ 3 × ULN in Gilbert's disease
Adequate hematologic and organ function as defined by the following criteria: ANC ≥ 1.5 × 10^9/L; Platelet count ≥ 100 × 10^9/L; ALT and AST ≤3 × ULN (≤ 5 x ULN if due to liver metastases); total serum bilirubin ≤ 1.5 × ULN or ≤ 3 × ULN in Gilbert's disease; Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 60 mL/min.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Site 0264 · Aurora, Colorado
- Site 0104 · Boston, Massachusetts
- Site 0111 · St Louis, Missouri
- Site 0173 · New York, New York
- Site 0259 · Durham, North Carolina
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify